March 9, 2000

AnVil Informatics, Inc. strengthens its Board of Directors
Appoints Dr. Allan M. Green and Dr. Frank Hurley

Lowell, MA -- AnVil Informatics, Inc. has announced the appointment of Allan M. Green, M.D.,Ph.D.,J.D. and Frank Hurley, Ph.D. to its Board of Directors.

Dr. Allan M. Green is currently Vice President of Pharmaceutical / Biomedical Products for ML Strategies and he is Of Counsel to the law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. He is also a director of North American Scientific, Inc., a publicly traded company involved in the development and sales of brachytherapy sources for cancer treatment. Dr. Green is a director of NEUROCHEM, Inc. and Select Therapeutics, Inc. Previously he was the Medical Director of New England Nuclear / DuPont Medical Products.

Dr. Frank Hurley was a co-founder of Biometric Research Institute (later known as BRI International) where he held a position of Chairman and Chief Scientific Officer until BRI's merger with Quintiles Transnational Corporation (NasdaqNM:QTRN). He served as Quintiles Chief Scientific Officer and currently is holding a position of Senior Scientist. He is also an Adjunct Professor of Biostatistics and Epidemiology at Georgetown University.

AnVil's President and Chief Executive Officer Howard Berke commented: "We are very pleased that Dr. Green and Dr. Hurley have agreed to join the Anvil Board. Their scientific expertise, business experience and credentials are outstanding and are directly relevant to Anvil's business scope." Mr. Berke added: "Dr. Green and Dr. Hurley bring impressive knowledge and experience to AnVil. The pharmaceutical and biotechnology industry is a strategic focus for Anvil, and Dr. Green and Dr. Hurley's counsel will be a real asset to the board and the company."

Dr. Green is a founder of Microfluidics International Corporation and NEUROCHEM, Inc. and has been actively involved in several other start-up ventures in the pharmaceutical industry. Dr. Green has substantial high-level operational and consulting experience in pharmaceutical industry. He authored many scientific papers in biochemistry and drug development and has organized a number of multi-disciplinary conferences on healthcare, pharmaceutical and funding issues.

Dr. Green received his S.B. in Economics and Ph.D. in Biochemistry and Metabolism from the Massachusetts Institute of Technology. He received his M.D from Case Western Reserve University School of Medicine and his J.D. from Boston College Law School.

Dr. Hurley's areas of expertise include the study design, analysis and reporting to the FDA of clinical trials involving pharmaceuticals, medical devices and diagnostic products. He has a keen understanding of all phases of the regulatory approval process, including multinational clinical studies, clinical trials management and post marketing surveillance. He is a nationally recognized authority on research strategy and study design for regulatory approval.

Dr. Hurley received his BS in Mathematics from Georgetown University and his Ph.D. in Biostatistics from John Hopkins University.

Drs. Green and Hurley are joining the existing Board members: Howard Berke, AnVil's founding CEO and Joseph McGuirl.

Howard Berke, AnVil's founding CEO, is a veteran in launching technology- oriented startups. He has been the founder/co-founder of seven start-up companies, some of which are publicly traded. Most recently, he was Chairman, CEO and President of White Pine Software (NasdaqNM: WPNE). He is familiar with every step throughout a company's growth, from concept stage to capital raising, from strategic partnership to IPO or acquisition. Mr. Berke has served as Chairman, CEO, President, Vice President and/or Board member with various high-growth start-ups. His industry involvement has spanned into medical device, healthcare, biotechnology, software and communications markets.

Joseph McGuirl , member of Board of Directors, is a seasoned executive from the health care industry. He is currently the Executive Director overseeing the technology licensing and commercialization efforts on the various UMass systems campuses. Through his previous positions, he has developed extensive knowledge and developed strong relationships with large and small companies throughout the healthcare industry. He established and served as Vice Chairman of HealthCare Ventures in New Jersey. For over 25 years, Mr. McGuirl held key executive positions in several pharmaceutical companies. He was the president and CEO at ScripTech Pharmaceuticals in Cambridge, MA. Before that, he was a business development executive at Hoffmann-LaRoche and W.R. Grace, leading a variety of licensing and corporate development activities.

Founded in 1999, AnVil Informatics, Inc. provides data mining and visualization services to leading pharmaceutical and biotechnology companies. AnVil's combination of unique, internally developed software and commercial tools allows for the exploration of complex, large and high dimensional data sets. In addition, AnVil's technical experts harness different properties of human perception such as color, texture and shape in the process of visualizing various attributes of the complex data and their full distributions. The resulting visualizations make conclusions more evident earlier in the decision making process and can greatly enhance every step of the client's decision making process--helping them to make informed decisions faster and more accurately. To learn more about AnVil's capabilities and offerings, visit the web site at www.anvilinformatics.com.